# TriArm Therapeutics

Source: https://onco.cc/companies/triarm-therapeutics/  
OnCo record `triarm-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TriArm Therapeutics develops CAR-T cell therapy made with a faster, virus-free manufacturing process. Its first product, ARM011, targets CD19 and is in an early trial in adults with B-cell acute lymphoblastic leukaemia that has come back or not responded.

## Summary

TriArm Therapeutics (Taiwan) Limited is based in Xizhi District, New Taipei City, and focuses on cell therapy and new drug development. Its FIT (fast-in-time) platform uses non-viral gene transfer, referencing a Sleeping Beauty transposon system, to make CAR-T cells in about two days. ARM011 is an autologous CD19 CAR-T product made on the FIT platform; the phase 1 trial NCT07066397 in relapsed or refractory B-cell acute lymphoblastic leukaemia, with fludarabine and cyclophosphamide conditioning, lists a site in Taipei, and in August 2025 the company said phase 1 trials had started in Taiwan and the United States. It said it was planning pre-IPO financing and a listing on the Taiwan Stock Exchange innovation board in 2026. Its first registered cancer trial, NCT07066397, was posted on ClinicalTrials.gov in July 2025.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: 創恩生技醫藥
- HQ: New Taipei City
- Type: cell-therapy
- Website: https://www.triarm.com.tw/

## Notes

- Founding year not stated on the company website.
- The cost reduction to one tenth claimed by the company is not independently verified and is left out of the summary.
- Whether the planned 2026 listing happened was not checked.
- Company website and August 2025 article read on 29 October 2026.

## Sources

- Official website: https://www.triarm.com.tw/
- ClinicalTrials.gov: phase 1 trial of ARM011 (NCT07066397): https://clinicaltrials.gov/study/NCT07066397

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [CD19](https://onco.cc/targets/cd19/)

---
JSON: https://onco.cc/api/v1/entities/triarm-therapeutics.json